Commonly used PGT testing solutions:
- Preimplantation genetic testing-aneuploidy (PGT-A): detects aneuploidies, or chromosomal abnormalities, across all 24 chromosomes (22 autosomes and the X and Y chromosomes)
- Preimplantation genetic testing-monogenic (PGT-M): identifies specific genetic variants in a single gene associated with known predisposition within the family
Advancements in next-generation sequencing (NGS) methods enable simple, scalable, and innovative sample-to-answer workflow solutions for PGT-A and PGT-M. NGS delivers fast results from precious samples, without the complexities that come with traditional genetic analysis tools.
Hear what your peers are saying about NGS and preimplantation genetic testing:
Webinar: Combined PGT-A and PGT-M analysis from a single biopsy in an IVF practice: Experience, learning and benefits
Learn the powerful benefits of running in-house PGT-A and PGT-M on the same NGS platform, with a single embryo biopsy. In-house control creates flexibility to respond to each patient scenario, thereby reducing unnecessary costs and time. And combining analyses from the same sample limits impact to the embryo, while producing comprehensive findings for greatest probability of pregnancy success and genetically healthy offspring.
Tee Sze Tian, MSc Clinical Embryology Group Chief Embryologist
TMC Fertility Centre
Webinar: The benefits of PGT-A, PGT-M and expanded carrier screening in IVF research
Follow the decision-making process and adoption of expanded carrier screening (ECS) and preimplantation genetic testing (PGT-A (aneuploidy) and PGT-M (monogenic) in patient care and reproductive genetics research labs.
Two presentations, followed by combined Q&A, cover:
- Importance of preconception testing and advantages of NGS technology
- Research data demonstrating:
- Carrier screening capabilities and influence on family planning
- Impact of PGT-A on pregnancy success rates
- Advantages of PGT-M over alternative approaches
- Carrier screening capabilities and influence on family planning
Dr Murat Cetinkaya, PhD
Istanbul Memorial Hospital Assisted Reproductive Technologies and Reproductive Genetic Center
Prof Volkan Baltaci, MD, PhD
CEO, Mikrogen Reproductive Genetics Company
